Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CRF1 receptor antagonist R317573 on CO2-induced anxiety in healthy subjects
2006-003659-19Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of R317573 in anxiety disorder and major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Efficacy of R317573 on CO2-induced anxiety. Started Sep 2006; status: completed.
02
Drugs
R317573
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-003659-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003659-19.